Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Christine ChevreauChristophe MassardAude FlechonRémy DelvaGwenaëlle GravisJean-Pierre LotzJacques-Olivier BayMarine Gross-GoupilKarim FizaziLoïc MoureyAngelo PaciJérôme GuittonFabienne ThomasBénédicte LelièvreJoseph CiccoliniSotheara MoeungYohan GalloisPascale OlivierStéphane CulineThomas FilleronEtienne ChatelutPublished in: Cancer medicine (2021)
The rates of complete and favorable responses were clinically relevant in this very poor risk population. Individual monitoring of carboplatin plasma concentration permitted to control more accurately the target AUC and avoided both underexposure and overexposure to the drug.
Keyphrases
- germ cell
- high dose
- phase ii study
- locally advanced
- open label
- acute lymphoblastic leukemia
- acute myeloid leukemia
- low dose
- phase iii
- stem cell transplantation
- diffuse large b cell lymphoma
- multiple myeloma
- placebo controlled
- rectal cancer
- adverse drug
- emergency department
- drug induced
- radiation therapy
- visible light